首页> 外文期刊>Journal of Medical Virology >Comparison of serologic responses between Kaposi's sarcoma-positive and -negative men who were seropositive for both human herpesvirus 8 and human immunodeficiency virus.
【24h】

Comparison of serologic responses between Kaposi's sarcoma-positive and -negative men who were seropositive for both human herpesvirus 8 and human immunodeficiency virus.

机译:对人疱疹病毒8和人免疫缺陷病毒都呈血清反应阳性的卡波西氏肉瘤阳性和阴性男性的血清学反应进行比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Although the introduction of HAART decreased substantially the incidence of Kaposi's sarcoma (KS), KS remains the most common cancer among individuals infected with human immunodeficiency virus (HIV). To define markers for progression to KS from the asymptomatic infection of human herpesvirus 8 (HHV-8), serologic responses against HHV-8 were compared between KS-negative and -positive men who were seropositive for both HIV and HHV-8. There was no difference in prevalence of detectable neutralizing antibodies between the two groups. The prevalence of anti-ORF73 antibodies among the dual seropositive patients increased in proportion to their risk of KS. In specimens obtained from 11 HIV+ patients at different intervals over a period of 4-12 years, increase of anti-ORF73 antibody titers was observed in the patients who developed KS but not in the patients who did not develop KS. These results suggest that there is a difference in serologic response against ORF73 between the HIV patients with and without KS. J. Med. Virol. 74:202-206, 2004. Copyright 2004 Wiley-Liss, Inc.
机译:尽管HAART的引入大大降低了卡波济肉瘤(KS)的发病率,但KS仍然是感染人类免疫缺陷病毒(HIV)的个体中最常见的癌症。为了确定无症状感染人类疱疹病毒8(HHV-8)演变为KS的标志物,比较了HIV和HHV-8血清阳性的KS阴性和阳性男性对HHV-8的血清学反应。两组之间可检测到的中和抗体发生率无差异。在双重血清反应阳性患者中,抗ORF73抗体的患病率与KS风险成正比。在4-12年内以不同间隔从11位HIV +患者获得的标本中,在患有KS的患者中观察到抗ORF73抗体滴度增加,而在未患有KS的患者中未观察到。这些结果表明,有和没有KS的HIV患者之间对ORF73的血清学反应存在差异。 J. Med。病毒。 74:202-206,2004年。版权所有2004 Wiley-Liss,Inc.。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号